Literature DB >> 3768240

Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.

J E Bredesen, P Kierulf.   

Abstract

The binding of disopyramide (DP) and mono-N-dealkyldisopyramide (MND) was measured by equilibrium dialysis in spiked whole blood (10 mumol l-1 DP or MND) from 50 patients having a serum concentration of alpha 1-acid glycoprotein (AAG) ranging from 0.40 to 3.14 g l-1, as well as in whole blood from five healthy subjects, spiked with different concentrations of AAG ranging from 0.61 to 3.33 g l-1. The binding ratio (moles bound divided by moles unbound) in all samples increased from 1.0 to 8.0 for DP and 0.6 to 3.3 for MND with increasing AAG concentrations. The binding varied according to the AAG concentrations both in patients and healthy subjects. Similarly total and free plasma concentrations of DP and MND were also measured. With increasing AAG concentrations the total concentrations measured increased from 9.0 to 15.9 mumol l-1 for DP and from 6.8 to 11.8 mumol l-1 for MND whereas the free concentrations decreased from 3.8 to 0.5 mumol l-1 for DP and from 5.0 to 2.0 mumol l-1 for MND. With increasing AAG concentrations the whole blood/plasma concentration ratio decreased from 1.11 and 1.47 to 0.63 and 0.85 for DP and MND respectively. The ratio between their concentration in cells and the unbound concentration in plasma, however, was constant over the whole AAG concentration range. The mean ratios for all samples were 3.0 and 3.1 for DP and MND respectively, indicating that both compounds are bound or distributed to the blood cells. The distribution of the drugs in whole blood changed according to increasing AAG concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768240      PMCID: PMC1401135          DOI: 10.1111/j.1365-2125.1986.tb02888.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

Review 1.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

2.  Increased plasma binding of quinidine after surgery: a preliminary report.

Authors:  D Fremstad; K Bergerud; J F Haffner; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

Review 3.  Pharmacology of commonly used antiarrhythmic drugs and comments on the use of therapeutic drug monitoring.

Authors:  O B Garfein
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

4.  Gas-chromatographic determination of disopyramide and its mono-N-dealkylated metabolite in serum with use of a nitrogen-selective detector.

Authors:  J E Bredesen
Journal:  Clin Chem       Date:  1980-04       Impact factor: 8.327

5.  Plasma binding of disopyramide.

Authors:  B M David; B W Madsen; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

6.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.

Authors:  M L Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

7.  Determination of (R)- and (S)-disopyramide in human plasma using a chiral alpha 1-acid glycoprotein column.

Authors:  J Hermansson; M Eriksson; O Nyquist
Journal:  J Chromatogr       Date:  1984-12-12

8.  Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.

Authors:  J J Lima; H Boudoulas; M Blanford
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

Review 9.  Reliability of antiarrhythmic drug plasma concentration monitoring.

Authors:  F Follath; U Ganzinger; E Schuetz
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

10.  Plasma binding of disopyramide and mono-N-dealkyldisopyramide.

Authors:  J E Bredesen; E Pike; P K Lunde
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

View more
  2 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 2.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.